Published in Women's Health Weekly, November 30th, 2006
Following market introduction, the company will conduct customary, FDA-required post approval studies to obtain market feedback on safety and effectiveness of the product.
Uroplasty President and CEO David B. Kaysen commented, "We have been selling Macroplastique in Europe since 1991 and this approval allows...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.